Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

NCT00189137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: ifosfamide and doxorubicin vs gemcitabine and docetaxel

Sponsor

University of Michigan Rogel Cancer Center